Care este prețul pentru Clarus Therapeutics Holdings, Inc. (CRXTQ)

Prețul pentru Clarus Therapeutics Holdings, Inc. (CRXTQ) este $0.0014

Care este capitalizarea de piață pentru Clarus Therapeutics Holdings, Inc. (CRXTQ)

Capitalizarea de piață pentru Clarus Therapeutics Holdings, Inc. (CRXTQ) este $72.83K

Venituri Clarus Therapeutics Holdings, Inc. (CRXTQ)

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

An	Venituri	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Venituri

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Venituri	Diferență de venituri	Țara
Eli Lilly and Company LLY.US	$79.67B	-	US
Johnson & Johnson JNJ.US	$97.93B	-	US
AbbVie Inc. ABBV.US	$64.39B	-	US
Roche Holding AG RO.SW	$77.52B	-	CH
Merck & Co., Inc. MRK.US	$66.40B	-	US

Companie

Venituri

Diferență de venituri

Țara